Volume 17, Number 3Review ArticlesImpact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice FollowiTreatment Impact AssessmentGregory C McMahonGordon A BrownKathleen F McGinleyOn October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)–based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation. [Rev Urol. 2015;17(3):171-177 doi: 10.3909/riu0696] © 2015 MedReviews®, LLCProstate cancer screeningProstate-specific antigenProstate biopsiesUnited States
Volume 19, Number 2Review ArticlesUtilization of Individualized Prostate Cancer and Genomic Biomarkers for the Practicing UrologistManagement UpdateGregory C McMahonGordon A BrownThomas J MuellerProstate cancer encompasses a complex heterogeneous disease spectrum. Physicians and patients are faced with the ambiguity of who should be screened, biopsied, rebiopsied, treated, or provided with adjuvant therapy. Personalized outcomes and treatments are especially important given the varied nature of the disease, plethora of treatment options, risks of morbidity, and quality of life. Today’s practicing urologist has a multitude of tests from which to choose, creating the difficult task of appropriate use. This review focuses on two blood-, one urine-, and five genomic-based tests, which, when used in the appropriate clinical setting, can facilitate the patient-physician decision-making process. [Rev Urol. 2017;19(2):97–105 doi:10.3909/riu0730] © 2017 MedReviews®, LLCProstate cancerGenomic testsPersonalized medicine
Volume 19, Number 4Practice ProfileSuccessfully Integrating Radium Ra 223 Dichloride Injection Into a Urology PracticeGregory C McMahonGordon A Brown[Rev Urol. 2017;19(4):248–251 doi: 10.3909/riu0782] © 2018 MedReviews®, LLC